Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Lundbeck Could Cheer Up Patient Investors

H.Lundbeck (OTCPK:HLUYY) isn't going to be an especially familiar name for many readers, as this Danish pharmaceutical company has largely sold through licensing partners in the United States. That said, this CNS specialist was the brains behind Forest Labs' (NYSE:FRX) highly successful depression drug Lexapro, and the company has some particularly interesting drugs in its pipeline. While the company's go-to-market strategy is still a work in progress and patent expirations are likely going to cut deeply into cash flows in the short term, this looks like a potentially undervalued name to consider.

Q4 Shows The High Price Of Transition

Lundbeck had an interesting fourth quarter, and one that got worse as you worked down the income...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details